Therefore, our data provide in vitro and in vivo evidence of HER2 subtype conversion from a HER2-negative tumor to a HER2-positive tumor, which support the use of HER2-targeted therapy for patients with recurrent HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.